Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on NewAmsterdam Pharma Company N.V — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

NewAmsterdam Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 13, 2024•over 1 year ago

Contract Type

partnership

BiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

NewAmsterdam Pharma Company N.V. announced the closing of an underwritten public offering of ordinary shares and pre-funded warrants. The net proceeds to the company from the offering were approximately $452.6 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Company Information

Company

NewAmsterdam Pharma Company N.V

About

NewAmsterdam Pharma Company N.V. is a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol.

Predictive Intelligence
Strategic

ML-powered predictions for NewAmsterdam Pharma Company N.V's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months